Faron Pharmaceuticals Oy - Asset Resilience Ratio
Faron Pharmaceuticals Oy (FARN) has an Asset Resilience Ratio of 0.11% as of June 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Faron Pharmaceuticals Oy to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Faron Pharmaceuticals Oy's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Faron Pharmaceuticals Oy (FARN) total assets.
Liquid Assets Composition Over Time
This chart breaks down Faron Pharmaceuticals Oy's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore FARN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX17.98K | 0.11% |
| Total Liquid Assets | GBX17.98K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Faron Pharmaceuticals Oy maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Faron Pharmaceuticals Oy Industry Peers by Asset Resilience Ratio
Compare Faron Pharmaceuticals Oy's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Faron Pharmaceuticals Oy (None–None)
The table below shows the annual Asset Resilience Ratio data for Faron Pharmaceuticals Oy.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more